

The Seventh WFH Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders

Welcome and introduction (8:45-9:00)

Perspectives on risk Chair: Magdy El Ekiaby (9:00-11:30)

- Risk-based decision making for blood safety – Judie Leach Bennett (9:00-9:30)
- The debate on MSM donors and discussion of future research – Mark Skinner and Nathan Schaefer (9:30-10:00)

Break (10:00-10:30)

- Efficacy of testing scenarios – Steve Kleinman (10:30-11:00)

Discussion (11:00-11:30)

Achieving a safe and affordable supply (11:30-5:00)

Health technology assessment in hemophilia – Chair: Brian O'Mahony (11:30-12:30)

- Albert Farrugia
- Sandy Schwartz

Lunch (12:30-2:00)

Update on inhibitors Chair: Mike Soucie (2:00-3:30)

- Carol Kasper
- Corien Eckhardt
- Elena Santagostino

Break (3:30-4:00)

Clinical trial issues Chair: Alok Srivastava (4:00-5:00)

- New treatment for hemophilia - changing options – Jerry Powell (4:00-4:30)
- Clinical trial design – Donna DiMichele (4:30-5:00)
- Harmonization of labeling – TBC (5:00-5:30)

Discussion (5:00-5:30)

Day two – Novel technologies Chair: David Page (9:00-12:30)

- Updates on gene transfer studies – Amit Nathwani (9:00-9:30)
- SD cryo – clinical experience update – Magdy El Ekiaby (9:30-10:00)

Break 10:00-10:30

Manufacturer's updates

- Debbie Kennedy – CSL Behring (10:30-11:00)
- Prasad Mathew – Bayer (11:00-11:30)
- Glenn Pierce – Biogen Idec Hemophilia (11:30-12:00)
- Kim Jacobsen – Novo Nordisk (12:00-12:30)

Lunch (12:30-2:00)

Closing discussion (2:00-3:00)